Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
Morille, M.
Montier, T.
Legras, P.
Carmoy, N.
Brodin, P.
Pitard, B.
Benoit, J. P.
Passirani, C.
Biomaterials, 2010-1
Jean-Pierre BENOIT
BENOIT Jean-Pierre
ORCID: 0000-0002-6178-7199
The advantages of nanomedicine in the treatment of visceral Leishmaniasis: between sound arguments and wishful thinking.
10.1080/17425247.2021.1853701
Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal Metastasis of Advanced Human Ovarian Cancer.
10.1021/acsami.0c05554
Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery.
10.1016/j.ejpb.2020.02.008
Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules.
10.1186/s12951-020-00589-3
Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice?
10.1016/j.actatropica.2019.105215
Self-assembled hyaluronan nanocapsules for the intracellular delivery of anticancer drugs.
10.1038/s41598-019-47995-8
Dodecyl creatine ester-loaded nanoemulsion as a promising therapy for creatine transporter deficiency.
10.2217/nnm-2019-0059
The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion.
10.1186/s40425-019-0536-x
Albendazole-lipid nanocapsules: Optimization, characterization and chemoprophylactic efficacy in mice infected with Echinococcus granulosus.
10.1016/j.exppara.2019.02.002
Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules.
10.1080/1061186x.2018.1547733
Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters.
10.1016/j.ejpb.2018.11.020
Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications.
10.1016/j.ijpharm.2019.118795
In vitro anti-cancer activity and pharmacokinetic evaluation of curcumin-loaded lipid nanocapsules.
10.1016/j.msec.2018.06.014
Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats.
10.2147/ijn.s146740
Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases?
10.1016/j.jconrel.2017.09.031
Experimental cystic echinococcosis therapy: In vitro and in vivo combined 5-fluorouracil/albendazole treatment.
10.1016/j.vetpar.2017.08.011
Ivermectin lipid-based nanocarriers as novel formulations against head lice.
10.1007/s00436-017-5510-2
Cytotoxicity and genotoxicity of lipid nanocapsules.
10.1016/j.tiv.2017.03.007
Lipid nanocapsules maintain full integrity after crossing a human intestinal epithelium model.
10.1016/j.jconrel.2017.03.005
Stealth nanocarriers based sterosomes using PEG post-insertion process.
10.1016/j.ejpb.2017.02.008
Efficient ferrocifen anticancer drug and Bcl-2 gene therapy using lipid nanocapsules on human melanoma xenograft in mouse.
10.1016/j.phrs.2017.01.031
Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.
10.1016/j.biomaterials.2016.04.010
How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?
10.1016/j.addr.2016.03.011
An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors.
10.1038/srep21417
Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications.
10.1007/s00436-016-4937-1
Inter-nanocarrier and nanocarrier-to-cell transfer assays demonstrate the risk of an immediate unloading of dye from labeled lipid nanocapsules.
10.1016/j.ejpb.2015.10.011
Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma.
10.1016/j.ijpharm.2015.09.062
Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice.
10.1016/j.actatropica.2015.09.016
Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice.
10.1016/j.nano.2015.02.010
In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor.
10.2217/nnm.14.124
Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
10.1016/j.ijpharm.2015.01.051
Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
10.1002/biot.201400162
FRET imaging approaches for in vitro and in vivo characterization of synthetic lipid nanoparticles.
10.1021/mp500329z
In vitro effect of 5-fluorouracil and paclitaxel on Echinococcus granulosus larvae and cells.
10.1016/j.actatropica.2014.07.013
Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring.
10.1016/j.jconrel.2014.05.042
Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules.
10.1016/j.nano.2014.05.002
Impact of interfacial cholesterol-anchored polyethylene glycol on sterol-rich non-phospholipid liposomes.
10.1016/j.jcis.2014.04.031
Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.
10.2147/ijn.s59134
An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: when the drug is a key player of the nanomedicine structure.
10.1039/c3sm52781f
Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency.
10.2217/nnm.13.205
Polyglutamic acid-PEG nanocapsules as long circulating carriers for the delivery of docetaxel.
10.1016/j.ejpb.2014.02.004
Tumour targeting of lipid nanocapsules grafted with cRGD peptides.
10.1016/j.ejpb.2013.12.006
Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery.
10.2147/ijn.s51837
In vivo evaluation of poly-l-asparagine nanocapsules as carriers for anti-cancer drug delivery.
10.1016/j.ijpharm.2013.09.038
Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide.
10.1016/j.ejps.2013.06.013
A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging.
10.1016/j.jconrel.2013.06.014
Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells.
10.1016/j.ijpharm.2013.06.013
Effect of particle size on the biodistribution of lipid nanocapsules: comparison between nuclear and fluorescence imaging and counting.
10.1016/j.ijpharm.2013.05.057
A review of the current status of siRNA nanomedicines in the treatment of cancer.
10.1016/j.biomaterials.2013.04.060
EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro.
10.1016/j.ijpharm.2013.04.001
Surface modification of lipid nanocapsules with polysaccharides: from physicochemical characteristics to in vivo aspects.
10.1016/j.actbio.2013.01.038
The effect of functionalizing lipid nanocapsules with NFL-TBS.40-63 peptide on their uptake by glioblastoma cells.
10.1016/j.biomaterials.2013.01.068
Perfluorocarbon-loaded lipid nanocapsules as oxygen sensors for tumor tissue pO₂ assessment.
10.1016/j.ejpb.2013.01.003
DNA nanocarriers for systemic administration: characterization and in vivo bioimaging in healthy mice.
10.1038/mtna.2012.56
Aqueous core nanocapsules: a new solution for encapsulating doxorubicin hydrochloride.
10.3109/03639045.2012.730526
Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model.
10.1002/jgm.2683
Relationship between affective symptoms and malnutrition severity in severe Anorexia Nervosa.
10.1371/journal.pone.0049380
Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.
10.1021/mp300370t
Smart nanocarriers for pH-triggered targeting and release of hydrophobic drugs.
10.1016/j.actbio.2012.08.049
Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models.
10.1016/j.nano.2012.08.005
Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient.
10.1099/jmm.0.042739-0
Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride.
10.1016/j.ijpharm.2012.06.026
Evaluation of surface deformability of lipid nanocapsules by drop tensiometer technique, and its experimental assessment by dialysis and tangential flow filtration.
10.1016/j.ijpharm.2012.06.019
Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules.
10.1016/j.ejpb.2012.04.012
siRNA LNCs--a novel platform of lipid nanocapsules for systemic siRNA administration.
10.1016/j.ejpb.2012.02.010
Serum-stable, long-circulating paclitaxel-loaded colloidal carriers decorated with a new amphiphilic PEG derivative.
10.1016/j.ijpharm.2012.01.038
[Conception and studies of micro and nanomedicines for brain applications].
10.1051/jbio/2012026
Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells.
10.1007/s11095-011-0624-1
In vitro expansion of human glioblastoma cells at non-physiological oxygen tension irreversibly alters subsequent in vivo aggressiveness and AC133 expression.
10.3892/ijo.2011.1271
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study.
10.2147/ijn.s25791
Protein-loaded PLGA-PEG-PLGA microspheres: a tool for cell therapy.
10.1016/j.ejps.2011.10.030
The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells.
10.1371/journal.pone.0025515
Passive and active tumour targeting with nanocarriers.
10.2174/157016311796798991
Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles.
10.1016/j.biomaterials.2011.07.057
OPA quantification of amino groups at the surface of lipidic nanocapsules (LNCs) for ligand coupling improvement.
10.1016/j.ijpharm.2011.07.028
A starch-based microparticulate system dedicated to diagnostic and therapeutic nuclear medicine applications.
10.1016/j.biomaterials.2011.07.007
Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules.
10.1016/j.biomaterials.2011.05.067
In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model.
10.1016/j.ijpharm.2011.06.031
Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect.
10.1007/s11095-011-0501-y
Stealth properties of poly(ethylene oxide)-based triblock copolymer micelles: a prerequisite for a pH-triggered targeting system.
10.1016/j.actbio.2011.06.014
Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133.
10.1016/j.ijpharm.2011.06.001
Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma.
10.1016/j.ijpharm.2011.04.037
Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model.
10.1371/journal.pone.0016926
Reverse micelle-loaded lipid nanocarriers: a novel drug delivery system for the sustained release of doxorubicin hydrochloride.
10.1016/j.ejpb.2011.02.015
Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration.
10.1016/j.ejpb.2011.01.021
Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy?
10.1016/j.ijpharm.2011.01.027
Tumor transfection after systemic injection of DNA lipid nanocapsules.
10.1016/j.biomaterials.2010.11.063
Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1.
10.1016/j.jconrel.2010.11.032
The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
10.2217/nnm.10.113
Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model.
10.1016/j.ijpharm.2010.10.015
Local implantation of doxorubicin drug eluting beads in rat glioma.
10.1016/j.ijpharm.2010.09.013
Methods for the functionalisation of nanoparticles: new insights and perspectives.
10.1002/chem.201000808
Reverse micelle-loaded lipid nano-emulsions: new technology for nano-encapsulation of hydrophilic materials.
10.1016/j.ijpharm.2010.07.039
Layer-by-layer surface modification of lipid nanocapsules.
10.1016/j.ejpb.2010.07.010
The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability.
10.1016/j.biomaterials.2010.06.024
Post-insertion into Lipid NanoCapsules (LNCs): From experimental aspects to mechanisms.
10.1016/j.ijpharm.2010.06.019
Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells.
10.1016/j.ejps.2010.04.015
Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s/o/w emulsion technique.
10.1016/j.ejpb.2010.03.005
Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice.
10.1007/s11095-009-0024-y
Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.
10.2217/nnm.09.110
New starch-based radiotracer for lung perfusion scintigraphy.
10.1007/s00259-009-1226-6
Non-viral nanosystems for systemic siRNA delivery.
10.1016/j.phrs.2009.11.013
Adult cell therapy for brain neuronal damages and the role of tissue engineering.
10.1016/j.biomaterials.2009.11.084
Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft.
10.1007/s11095-009-0006-0
Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers.
10.1007/s11095-009-9986-z
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
10.1016/j.biomaterials.2009.09.044
Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules.
10.1021/la901565q
In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy.
10.1007/s11060-009-0012-4
Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis.
10.1016/j.jconrel.2009.08.010
Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel.
10.1016/j.ejpb.2009.06.013
The gastrointestinal stability of lipid nanocapsules.
10.1016/j.ijpharm.2009.05.069
Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting.
10.1016/j.ijpharm.2009.05.065
Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model.
10.1016/j.ijpharm.2009.05.031
The adaptation of lipid nanocapsule formulations for blood administration in animals.
10.1016/j.ijpharm.2009.05.033
Interactions between poly(ethylene glycol) and protein in dichloromethane/water emulsions. 2. Conditions required to obtain spontaneous emulsification allowing the formation of bioresorbable poly(D,L lactic acid) microparticles.
10.1016/j.ejpb.2009.04.011
Lipid nanocapsules: a new platform for nanomedicine.
10.1016/j.ijpharm.2009.04.026
The encapsulation of DNA molecules within biomimetic lipid nanocapsules.
10.1016/j.biomaterials.2009.03.009
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors.
10.1016/j.biomaterials.2009.01.003
Imaging E-selectin expression following traumatic brain injury in the rat using a targeted USPIO contrast agent.
10.1007/s10334-008-0161-z
Synthesis and pH-dependent micellization of diblock copolymer mixtures.
10.1016/j.jcis.2008.09.080
Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas.
10.1016/j.jconrel.2008.05.027
[Local chemotherapy of malignant glioma: from syringe injections to nanotechnology].
10.1016/j.neurol.2008.03.015
[Oral bioavailability and drug/carrier particulate systems].
10.1051/medsci/20082467659
Progress in developing cationic vectors for non-viral systemic gene therapy against cancer.
10.1016/j.biomaterials.2008.04.036
188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas.
10.1007/s00259-008-0735-z
Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres.
10.1016/j.ejpb.2008.03.006
Design and production of nanoparticles formulated from nano-emulsion templates-a review.
10.1016/j.jconrel.2008.02.007
Interactions between poly(ethylene glycol) and protein in dichloromethane/water emulsions: a study of interfacial properties.
10.1016/j.ejpb.2008.01.021
Lipid nanocapsules for intracellular drug delivery of anticancer drugs.
10.1166/jnn.2007.18114
How to achieve sustained and complete protein release from PLGA-based microparticles?
10.1016/j.ijpharm.2007.11.012
Brain targeting using novel lipid nanovectors.
10.1016/j.jconrel.2007.11.001
Active targeting of brain tumors using nanocarriers.
10.1016/j.biomaterials.2007.06.011
Perfusional deficit and the dynamics of cerebral edemas in experimental traumatic brain injury using perfusion and diffusion-weighted magnetic resonance imaging.
10.1089/neu.2006.0136
The influence of headgroup structure and fatty acyl chain saturation of phospholipids on monolayer behavior: a comparative rheological study.
10.1016/j.chemphyslip.2007.06.226
In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel.
10.1016/j.ijpharm.2007.06.014
5-ASA loaded chitosan-Ca-alginate microparticles: Preparation and physicochemical characterization.
10.1016/j.ijpharm.2007.05.059
Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments.
10.1016/j.biomaterials.2007.05.014
Nano-emulsions and nanocapsules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion.
10.1016/j.ijpharm.2007.04.027
Salting-out effect induced by temperature cycling on a water/nonionic surfactant/oil system.
10.1021/jp0664768
Evaluating SPIO-labelled cell MR efficiency by three-dimensional quantitative T2* MRI.
10.1002/nbm.1084
Pharmacologically active microcarriers releasing glial cell line - derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats.
10.1016/j.biomaterials.2006.12.021
Evaluation of particulate systems supporting tumor cell fractions in a preventive vaccination against intracranial rat glioma.
10.3171/jns.2006.105.5.745
Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification.
10.1080/03639040600683501
Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake.
10.1002/jbm.a.30711
Pegylated nanocapsules produced by an organic solvent-free method: Evaluation of their stealth properties.
10.1007/s11095-006-9061-y
A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats.
10.1158/1535-7163.mct-06-0289
The brain tissue response to biodegradable poly(methylidene malonate 2.1.2)-based microspheres in the rat.
10.1016/j.biomaterials.2006.04.045
Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.
10.1007/s11095-006-0022-2
Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent.
10.1016/j.ijpharm.2006.04.007
Parameters influencing the stealthiness of colloidal drug delivery systems.
10.1016/j.biomaterials.2006.03.039
Development and characterization of interleukin-18-loaded biodegradable microspheres.
10.1016/j.ijpharm.2005.07.029
In vitro investigation of lipid implants as a controlled release system for interleukin-18.
10.1016/j.ijpharm.2005.08.031
Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition.
10.1016/j.jconrel.2006.02.014
Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory.
10.1016/j.ijpharm.2005.07.030
Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts.
10.1016/j.ejpb.2005.11.006
Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization.
10.1016/j.ijpharm.2005.07.028
Novel composite core-shell nanoparticles as busulfan carriers.
10.1016/j.jconrel.2006.01.002
Dynamics of cerebral edema and the apparent diffusion coefficient of water changes in patients with severe traumatic brain injury. A prospective MRI study.
10.1007/s00330-005-0086-0
99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution.
10.1007/s00259-005-0007-0
Development of new polymer-based particulate systems for anti-glioma vaccination.
10.1016/j.ijpharm.2005.10.046
Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.
10.1007/s11095-005-7147-6
Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants.
10.1016/j.biomaterials.2005.04.004
Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat.
10.1258/0023677054307051
Biopharmaceutics of intrathecal baclofen-loaded microparticles in a goat model.
10.1016/j.ijpharm.2005.03.025
Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation.
10.1016/j.ejpb.2005.04.004
Effect of stabilized iodized oil emulsion on experimentally induced hepatocellular carcinoma in rats.
10.1097/01.rvi.0000156192.89569.0c
Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface.
10.1002/elps.200410145
Pharmacologically active microcarriers: a tool for cell therapy.
10.1016/j.biomaterials.2004.09.042
Interactions between hen egg-white lysozyme, PEG2,000, and PLA50 at the air-water interface.
10.1016/j.colsurfb.2005.02.003
Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model.
10.1016/j.ejpb.2004.08.013
Drug delivery into the brain using poly(lactide-co-glycolide) microspheres.
10.1517/17425247.2.2.363
Combining polymeric devices and stem cells for the treatment of neurological disorders: a promising therapeutic approach.
10.2174/1389450053344885
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial.
10.1227/01.neu.0000144982.82068.a2
Preparation of PLGA microparticles by an emulsion-extraction process using glycofurol as polymer solvent.
10.1007/s11095-004-7693-3
188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma.
10.1097/00006231-200410000-00004
Influence of 5-fluorouracil-loaded microsphere formulation on efficient rat glioma radiosensitization.
10.1023/b:pham.0000041448.22771.48
Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment.
10.1016/j.ijpharm.2004.03.018
Striatal tyrosine hydroxylase immunoreactive neurons are induced by L-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats.
10.1016/j.neulet.2004.02.068
Effect of the size of biodegradable microparticles on drug release: experiment and theory.
10.1016/j.jconrel.2004.01.011
In vitro study of GDNF release from biodegradable PLGA microspheres.
10.1016/j.jconrel.2003.12.012
Development of novel 5-FU-loaded poly(methylidene malonate 2.1.2)-based microspheres for the treatment of brain cancers.
10.1016/s0939-6411(03)00146-2
Pitfalls in the detection of lipid vectors in neural cell culture and in brain tissue.
10.1002/jbm.a.20060
Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease.
10.1016/s0142-9612(03)00601-x
Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.
10.1016/j.neulet.2003.11.051
Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes.
10.1016/j.jconrel.2003.10.024
In vivo evaluation of pharmacologically active microcarriers releasing nerve growth factor and conveying PC12 cells.
10.3727/000000004783983675
Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma.
10.1002/cncr.11922
Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma.
10.1016/j.ijpharm.2003.08.014
Physico-chemical stability of colloidal lipid particles.
10.1016/s0142-9612(03)00331-4
Mathematical modeling of drug release from bioerodible microparticles: effect of gamma-irradiation.
10.1016/s0939-6411(03)00104-8
Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility.
10.1016/s0142-9612(03)00161-3
Spectroscopic studies on poly(ethylene glycol)-lysozyme interactions.
10.1016/s0378-5173(03)00258-8
Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats.
10.1002/cncr.11388
Simple liquid-chromatographic method for Nile Red quantification in cell culture in spite of photobleaching.
10.1016/s1570-0232(02)00962-5
Interfacial properties of adsorbed films made of a PEG2000 and PLA50 mixture or a copolymer at the dichloromethane-water interface.
10.1016/s0021-9797(02)00235-7
The influence of lipid nanocapsule composition on their size distribution.
10.1016/s0928-0987(02)00241-5
A supercritical fluid-based coating technology. 3: preparation and characterization of bovine serum albumin particles coated with lipids.
10.1080/02652040210162630
A supercritical fluid-based coating technology. 2: solubility considerations.
10.1080/02652040210162649
A supercritical fluid-based coating technology 1: process considerations.
10.3109/02652040309178051
Implantable drug-releasing biodegradable microspheres for local treatment of brain glioma.
10.1007/978-3-7091-6090-9_9
A new mathematical model quantifying drug release from bioerodible microparticles using Monte Carlo simulations.
10.1023/a:1021457911533
New lipid nanocapsules exhibit sustained release properties for amiodarone.
10.1016/s0168-3659(02)00258-4
Influence of some formulation parameters on lysozyme adsorption and on its stability in solution.
10.1016/s0378-5173(02)00226-0
Properties of polyethylene glycol 660 12-hydroxy stearate at a triglyceride/water interface.
10.1016/s0378-5173(02)00144-8
Microencapsulation of protein particles within lipids using a novel supercritical fluid process.
10.1016/s0378-5173(02)00149-7
A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheres.
10.1023/a:1016482809810
A quantitative method for the determination of amphiphilic drug release kinetics from nanoparticles using a Langmuir balance.
10.1021/ac025581k
A novel phase inversion-based process for the preparation of lipid nanocarriers.
10.1023/a:1016121319668
Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
10.1002/syn.10063
PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release.
10.1016/s0928-0987(02)00023-4
Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-fluorouracil-loaded PLGA microspheres.
10.1016/s0939-6411(02)00011-5
Development and characterization of solid lipid nanoparticles loaded with magnetite.
10.1016/s0378-5173(01)00936-x
Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: a magnetic resonance imaging study.
10.1002/nbm.720
Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy.
10.3171/jns.2001.95.3.0489
PLGA microsphere bioburden evaluation for radiosterilization dose selection.
10.1080/02652040010019424
Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons.
10.1016/s0142-9612(00)00141-1
Development of microspheres for neurological disorders: from basics to clinical applications.
10.1016/s0168-3659(99)00250-3
Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage.
10.1006/exnr.1999.7253
Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres?
10.1023/a:1014818118224
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study.
10.1002/(sici)1097-0142(19990715)86:2<325::aid-cncr17>3.0.co;2-s
Modulated release of IdUrd from poly (D,L-lactide-co-glycolide) microspheres by addition of poly (D,L-lactide) oligomers.
10.1016/s0168-3659(98)00165-5
Rhizobacteria microencapsulation: properties of microparticles obtained by spray-drying.
10.1080/026520499289194
Development of 5-iodo-2'-deoxyuridine milling process to reduce initial burst release from PLGA microparticles.
10.1016/s0378-5173(98)00380-9
Direct qualitative and quantitative characterization of a radiosensitizer, 5-iodo-2'-deoxyuridine within biodegradable polymeric microspheres by FT-Raman spectroscopy.
10.1039/a806678g
The characterization and release kinetics evaluation of baclofen microspheres designed for intrathecal injection.
10.1016/s0378-5173(98)00350-0
NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability.
10.1016/s0168-3659(98)00086-8
Microencapsulation of rhizobacteria by spray-drying: formulation and survival studies.
10.3109/02652049809008247
Physical aging of progesterone-loaded poly(D,L,-lactide-co-glycolide) microspheres.
10.1023/a:1011991624411
Internal morphology of poly(D,L-lactide-co-glycolide) BCNU-loaded microspheres. Influence on drug stability.
10.1016/s0939-6411(97)00120-3
Tensioactivity and supramolecular organization of the palmitoyl prodrug of timolol.
10.1023/a:1012047231989
Surface characterization of poly(alpha-hydroxy acid) microspheres prepared by a solvent evaporation/extraction process.
10.1016/s0142-9612(96)00102-0
Preparation, purification and morphology of polymeric nanoparticles as drug carriers.
10.1016/0031-6865(95)00059-3
Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats.
10.1097/00006123-199607000-00023
Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of the microencapsulation procedure.
10.3109/02652049609006802
Diffuse scattering in protein crystallography.
10.1017/s0033583500003048
Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers.
10.1111/j.2042-7158.1995.tb05760.x
In vitro study of the anti-leishmanial activity of biodegradable nanoparticles.
10.3109/10611869509015929
Fate and biocompatibility of three types of microspheres implanted into the brain.
10.1002/jbm.820280913
Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres.
10.1227/00006123-199406000-00016
End-chain radiolabeling and in vitro stability studies of radiolabeled poly(hydroxy acid) nanoparticles.
10.1002/jps.2600830618
Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres.
10.1016/0142-9612(93)90151-q
Preliminary evaluation of a series of amphiphilic timolol prodrugs: possible evidence for transscleral absorption.
10.1089/jop.1993.9.141
Ibuprofen-loaded ethylcellulose microspheres: analysis of the matrix structure by thermal analysis.
10.1002/jps.2600801106
A physicochemical study of the morphology of progesterone-loaded microspheres fabricated from poly(D,L-lactide-co-glycolide).
10.1002/jbm.820250509
Ibuprofen-loaded ethylcellulose microspheres: release studies and analysis of the matrix structure through the Higuchi model.
10.3109/02652049009040479
Influence of average molecular weights of poly(DL-lactic acid-co-glycolic acid) copolymers 50/50 on phase separation and in vitro drug release from microspheres.
10.1023/a:1015945806917
In vitro and in vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method.
10.1016/0142-9612(89)90063-x
In-vitro evaluation of filaricidal activity of GABA and 1,3-dipalmitoyl-2-(4-aminobutyryl)glycerol HCl: a diglyceride prodrug.
10.1111/j.2042-7158.1989.tb06428.x
Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases.
10.1089/sct.1989.5.1
Ion-exchange albumin microcapsules of doxorubicin: an in vitro release kinetic evaluation.
10.3109/02652048809064170
Magnetically responsive microspheres for the pulsed delivery of insulin.
10.1016/0024-3205(88)90009-4
Binding mechanism of doxorubicin in ion-exchange albumin microcapsules.
10.1002/jps.2600760613
Calcium and thiocyanate interactions with crosslinked albumin microcapsules: influence of the reticulation rate.
10.1016/0142-9612(87)90066-4
5-Fluorouracil:carnauba wax microspheres for chemoembolization: an in vitro evaluation.
10.1002/jps.2600750905
Formation and characterization of cisplatin loaded poly(d,l-lactide) microspheres for chemoembolization.
10.1002/jps.2600750805
The formation and characterization of hydrocortisone-loaded poly((+/-)-lactide) microspheres.
10.1111/j.2042-7158.1986.tb04561.x
Characterization of drug-loaded poly(d,l-lactide) microspheres.
10.1002/jps.2600731215
Biodegradable cross-linked albumin microcapsules for embolization.
10.3109/02652048409031544
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections
10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism
10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria
10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis
10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis
10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters
10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization
10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin
10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection
10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1
10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo
10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges
10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis
10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system
10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays
10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches
10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways
10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings
10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis
10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence
10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis
10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200076a
High-content screening in infectious diseases
10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ
10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery
10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure
10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors
10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems
10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP
10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans
10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity
10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis
10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva
10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images
10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues
10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis
10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents
10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence
10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection
10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence
10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis
10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity
10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics
10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions
10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine
10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6
10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens
10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex
10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex
10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides
10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro
10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase
10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides
10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase
10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides
10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions
10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus
10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays
10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors
10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis
10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation
10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis
10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase
10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening
10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections
10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation
10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters
10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis
10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells
10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria
10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation
10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies.
10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.
10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis.
10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Worms' Antimicrobial Peptides.
10.3390/md17090512
T(oo)bAd.
10.1038/s41589-019-0347-x
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Cell microbiology interview
10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts
10.1099/mgen.0.000505
Marie Morille
Morille Marie
ORCID: 0000-0001-8224-7346
Liposomes, lipid nanocapsules and smartCrystals®: A comparative study for an effective quercetin delivery to the skin
10.1016/j.ijpharm.2018.03.019
Tripartite polyionic complex (PIC) micelles as non-viral vectors for mesenchymal stem cell siRNA transfection
10.1039/c7bm00384f
Dermal quercetin lipid nanocapsules: Influence of the formulation on antioxidant activity and cellular protection against hydrogen peroxide
10.1016/j.ijpharm.2016.12.043
Quercetin topical application, from conventional dosage forms to nanodosage forms
10.1016/j.ejpb.2016.08.011
Non-viral gene activated matrices for mesenchymal stem cells based tissue engineering of bone and cartilage
10.1016/j.biomaterials.2016.07.017
Dermal quercetin smartCrystals®: Formulation development, antioxidant activity and cellular safety
10.1016/j.ejpb.2016.03.004
PLGA-based microcarriers induce mesenchymal stem cell chondrogenesis and stimulate cartilage repair in osteoarthritis
10.1016/j.biomaterials.2016.02.022
Scaffolds for controlled release of cartilage growth factors
10.1007/978-1-4939-2938-2_12
New PLGA-P188-PLGA matrix enhances TGF-β3 release from pharmacologically active microcarriers and promotes chondrogenesis of mesenchymal stem cells
10.1016/j.jconrel.2013.04.017
DNA nanocarriers for systemic administration: Characterization and in vivo bioimaging in healthy mice
10.1038/mtna.2012.56
Near-infrared optical imaging of nucleic acid nanocarriers in vivo
10.1007/978-1-62703-140-0_5
Implication of oxidative stress in size-dependent toxicity of silica nanoparticles in kidney cells
10.1016/j.tox.2012.05.010
Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells
10.1007/s11095-011-0624-1
Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect
10.1007/s11095-011-0501-y
Stealth properties of poly(ethylene oxide)-based triblock copolymer micelles: A prerequisite for a pH-triggered targeting system
10.1016/j.actbio.2011.06.014
Tumor transfection after systemic injection of DNA lipid nanocapsules
10.1016/j.biomaterials.2010.11.063
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
10.1016/j.biomaterials.2009.09.044
Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting
10.1016/j.ijpharm.2009.05.065
Progress in developing cationic vectors for non-viral systemic gene therapy against cancer
10.1016/j.biomaterials.2008.04.036
Elaboration of materials with functionality gradients by assembly of chitosan-collagen microspheres produced by microfluidics
10.7569/JRM.2017.634186
Fluorescent Biosensor for Detection of the R248Q Aggregation‐Prone Mutant of p53
{10.1002/cbic.201800531}
Polyoxazolines based lipid nanocapsules for topical delivery of antioxidants
10.1016/j.ijpharm.2020.119126
Post-production modifications of murine mesenchymal stem cell (mMSC) derived extracellular vesicles (EVs) and impact on their cellular interaction
10.1016/j.biomaterials.2019.119675
Polyoxazolines based mixed micelles as PEG free formulations for an effective quercetin antioxidant topical delivery
10.1016/j.ijpharm.2019.118516
Near-Infrared Optical Imaging of Nucleic Acid Nanocarriers In Vivo
10.1007/978-1-4939-9092-4_23
PySHS: Python Open Source Software for Second Harmonic Scattering
10.1021/acs.jcim.0c00789
Degradable double hydrophilic block copolymers and tripartite polyionic complex micelles thereof for small interfering ribonucleic acids (siRNA) delivery
10.1016/j.jcis.2020.07.057
Exosomal melanotransferrin as a potential biomarker for metastatic melanoma
10.1101/2020.11.09.373852
Nanotechnologies for Intracellular Protein Delivery: Recent Progress in Inorganic and Organic Nanocarriers
10.1002/adtp.202100009
Interest of extracellular vesicles in regards to lipid nanoparticle based systems for intracellular protein delivery
10.1016/j.addr.2021.113837
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton.
10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling.
10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone.
10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection.
10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection.
10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis.
10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening.
10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces.
10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR.
10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce.
10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens.
10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water.
10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries.
10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment.
10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables.
10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system.
10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis.
10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids.
10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.
10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages.
10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis.
10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs.
10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis.
10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections.
10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.
10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.
10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization.
10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro.
10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin].
10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.
10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo.
10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges].
10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays.
10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways.
10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.
10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence.
10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings.
10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
10.1371/journal.pone.0026675
High-content screening in infectious diseases.
10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling.
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ.
10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems.
10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure.
10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.
10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity.
10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans].
10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis.
10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva.
10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence.
10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents.
10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence.
10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine.
10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity.
10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics.
10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6.
10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex.
10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family.
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.
10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.
10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant.
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides.
10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
